In search of hepatitis C virus receptors

Clinics in Liver Disease

Volumn 5, Issue 4, 2001, Pages 873-893

  Flint, Mike ^a   Quinn, Elizabeth R ^a   Levy, Shoshana ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; HEPARIN; LOW DENSITY LIPOPROTEIN RECEPTOR; VIRUS RECEPTOR; VIRUS RNA;

CELL INTERACTION; CHIMERA; HEPATITIS C; HEPATITIS C VIRUS; LIVER CELL; MONONUCLEAR CELL; NONHUMAN; REVIEW; VIRUS TYPING;

EID: 0034773236     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(05)70199-9     Document Type: Article

References (89)

1. Nonrandom distribution of hepatitis C virus quasispecies in plasma and peripheral blood mononuclear cell subsets
2. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor
3. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81
4. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins
5. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus
6. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
7. Functions of cell surface heparan sulfate proteoglycans
8. Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients
9. Hepatitis C virus: Buoyant density of the factor VIII-derived isolate in sucrose
10. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments
11. Mixed cryoglobulinemia in hepatitis C patients. GERMIVIC
12. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate
13. Persistence of HCV despite antibodies to both putative envelope glycoproteins
14. Vaccination of chimpanzees against infection by hepatitis C virus
15. In vitro infection of peripheral blood mononuclear cells by hepatitis C virus
16. Isolation and characterization of human monoclonal antibodies against hepatitis C virus envelope glycoproteins
17. Formation of native hepatitis C virus glycoprotein complexes
18. Folding, assembly and subcellular localization of hepatitis C virus glycoproteins
19. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization
20. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein
21. Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein
22. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81
23. The role of the hepatitis C virus glycoproteins in infection
24. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein
25. Characterization of modified hepatitis C virus E2 proteins expressed on the cell surface
26. Quasispecies in viral persistence and pathogenesis of hepatitis C virus
27. Suramin blocks hepatitis C binding to human hepatoma cells in vitro
28. Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties
29. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes
30. Virus receptors: Binding, adhesion strengthening, and changes in viral structure
31. Evaluation of hepatitis C virus glycoprotein E2 for vaccine design: An endoplasmic reticulum-retained recombinant protein is superior to secreted recombinant protein and DNA-based vaccine candidates
32. Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2
33. Hypervariable regions in the putative glycoprotein of hepatitis C virus
34. Equilibrium centrifugation studies of hepatitis C virus evidence for circulating immune complexes
35. A model of leukocyte adhesion to vascular endothelium
36. Generation of transmissible hepatitis C virions from a molecular clone in chimpanzees
37. High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C
38. Hepatitis C virus particle detected by immunoelectron microscopic study
39. Buoyant density of hepatitis C virus recovered from infected hosts: Two different features in sucrose equilibrium density-gradient centrifugation related to degree of liver inflammation
40. Measles: Immunosuppression, interleukin-12, and complement receptors
41. Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection
42. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus
43. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA
44. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus
45. Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR
46. CD81 (TAPA-1): A molecule involved in signal transduction and cell adhesion in the immune system
47. The tetraspanin superfamily: Molecular facilitators
48. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection
49. Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells
50. Characterization of truncated forms of hepatitis C virus glycoproteins
51. Extraordinary low density of hepatitis C virus estimated by sucrose density gradient centrifugation and the polymerase chain reaction
52. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus
53. Peripheral blood leukocytes serve as a possible extrahepatic site for hepatitis C virus replication
54. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: Analysis of regions critical for glycoprotein aggregation and CD81 binding
55. Structure-function analysis of hepatitis C virus envelope-CD81 binding
56. Binding of hepatitis C virus to CD81
57. Exploitation of cellular signaling by HIV-1: Unwelcome guests with master keys that signal their entry
58. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins
59. Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: Hypervariable region 1 as a decoy
60. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: Proposals for standardization
61. A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: Cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells
62. Microbial adherence to and invasion through proteoglycans
63. Heparan sulfate: A piece of information
64. The rheumatoid factor response in the etiology of mixed cryoglobulins associated with hepatitis C virus infection
65. Distribution of hepatitis C virus (HCV) RNA in whole blood and blood cell fractions: Plasma HCV RNA analysis underestimates circulating virus load
66. Cellular receptors for viruses: Links to tropism and pathogenesis
67. Establishment of persistent hepatitis C virus infection and replication in vitro
68. Hepatitis C virus: Detection of intracellular virus particles by electron microscopy
69. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses
70. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures
71. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line
72. Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro
73. Variability of hepatitis C virus
74. Protein and 33-nm particle associated with nucleocapsid of hepatitis C virus recovered from the circulation of infected hosts
75. Cell fusion activity of hepatitis C virus envelope proteins
76. A structurally flexible and antigenically variable N-terminal domain of the hepatitis C virus E2/NS1 protein: Implication for an escape from antibody
77. Association of hepatitis C virus in human sera with beta-lipoprotein
78. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins
79. Detection of replicative form of hepatitis C virus RNA in peripheral blood mononuclear cells
80. Sequence variation in hepatitis C viral isolates
81. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: Potential role in chronic HCV infections
82. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor
83. Transmission of hepatitis C virus infection to tree shrews
84. A model for the hepatitis C virus envelope glycoprotein E2
85. Hepatitis C virus: An infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras
86. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee
87. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo
88. Monoclonal antibodies to the hypervariable region 1 of hepatitis C virus capture virus and inhibit virus adsorption to susceptible cells in vitro
89. Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment